Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185057 | 0.90 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1TDP1KMT2AMMP8 | |
| SCHEMBL28464077 | 0.87 | MMP8 (0.50) | ALDH1A1KDM4EMAPTKMT2AMMP8 | |
| SCHEMBL1667154 | 0.83 | STAT3 (0.44) | ALDH1A1MAPTTDP1KMT2ALMNA | |
| SCHEMBL17290387 | 0.83 | BRD4 (0.52) | ALDH1A1L3MBTL1KMT2AMEN1NPC1 | |
| SCHEMBL17290963 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL17295108 | 0.83 | BRD4 (0.52) | ALDH1A1L3MBTL1KMT2AMEN1NPC1 | |
| SCHEMBL5431219 | 0.83 | RAB9A (0.47) | ALDH1A1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL11031397 | 0.82 | KMT2A (0.62) | ALDH1A1KMT2AMMP8LMNAMEN1 | |
| SCHEMBL29311540 | 0.81 | TDP1 (0.41) | ALDH1A1L3MBTL1MAPTTDP1LMNA | |
| SCHEMBL28152310 | 0.81 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1TDP1KMT2AMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | ALDH1A1 352/4885L3MBTL1 2793/4885KDM4E 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.